|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.420 HKD | +1.14% |
|
+0.45% | -7.53% |
| Jan. 21 | CSPC Pharmaceutical Gets China Nod for Registration of Tumor Drug | MT |
| Jan. 20 | CSPC Pharmaceutical Group Limited Announces Regorafenib Tablets Obtains Drug Registration Approval | CI |
| Capitalization | 50.84B 6.53B 6.21B 5.91B 5.23B 9.35B 563B 10.32B 71.22B 26.16B 233B 24.46B 23.98B 1,016B | P/E ratio 2024 * |
8.88x | P/E ratio 2025 * | 8.66x |
|---|---|---|---|---|---|
| Enterprise value | 34.71B 4.46B 4.24B 4.03B 3.57B 6.39B 384B 7.05B 48.62B 17.86B 159B 16.7B 16.37B 694B | EV / Sales 2024 * |
1.05x | EV / Sales 2025 * | 0.94x |
| Free-Float |
-
| Yield 2024 * |
4.96% | Yield 2025 * | 4.96% |
More valuation ratios
* Estimated data
More news
More recommendations
More press releases
More news
| 1 day | +1.14% | ||
| 1 week | +0.45% | ||
| Current month | -7.53% | ||
| 1 month | -7.92% | ||
| 3 months | -29.05% | ||
| 6 months | -24.32% | ||
| Current year | -7.53% |
1 week
4.35
4.54
1 month
4.274.84
Current year
4.274.74
1 year
4.277.83
3 years
4.2710.36
5 years
4.2712.68
10 years
3.0313.93
| Director | Title | Age | Since |
|---|---|---|---|
Cui Long Zhang
CEO | Chief Executive Officer | 56 | 2019-05-20 |
Yong-Jun Liu
PRN | Corporate Officer/Principal | - | 2024-09-08 |
Tai On Lo
SEC | Corporate Secretary | 70 | 2020-12-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 71 | 2011-08-25 |
Wei Dong Pan
BRD | Director/Board Member | 56 | 2010-02-24 |
Huai Yu Wang
BRD | Director/Board Member | 62 | 2010-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.05% | 0 M€ | -20.08% | - | |
| 2.02% | 0 M€ | -27.92% | ||
| 1.07% | 0 M€ | -2.90% | - | |
| 0.99% | 0 M€ | -14.14% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +1.14% | +0.45% | -27.54% | -52.22% | 6.53B | ||
| +2.45% | +8.22% | +25.14% | +227.99% | 707B | ||
| +7.13% | +8.13% | -14.02% | +99.10% | 389B | ||
| +0.12% | -0.14% | -7.98% | -12.41% | 353B | ||
| -0.22% | -0.73% | +3.13% | +27.96% | 301B | ||
| +0.18% | +3.58% | +13.60% | -20.60% | 244B | ||
| -1.12% | -2.42% | -20.46% | +20.25% | 242B | ||
| +0.04% | +1.02% | +5.76% | +30.63% | 214B | ||
| 0.00% | +1.05% | -2.68% | +16.89% | 199B | ||
| -0.89% | +1.22% | -11.23% | +22.39% | 148B | ||
| Average | +0.88% | +2.17% | -3.63% | +36.00% | 280.5B | |
| Weighted average by Cap. | +1.48% | +3.45% | +2.73% | +77.23% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 32.97B 4.23B 4.03B 3.83B 3.39B 6.07B 365B 6.7B 46.19B 16.96B 151B 15.86B 15.55B 659B | 34.26B 4.4B 4.18B 3.98B 3.52B 6.3B 379B 6.96B 47.99B 17.62B 157B 16.48B 16.16B 685B |
| Net income | 5.56B 714M 679M 646M 572M 1.02B 61.54B 1.13B 7.79B 2.86B 25.48B 2.68B 2.62B 111B | 5.95B 764M 727M 691M 612M 1.09B 65.85B 1.21B 8.34B 3.06B 27.26B 2.86B 2.81B 119B |
| Net Debt | -16.13B -2.07B -1.97B -1.87B -1.66B -2.97B -179B -3.28B -22.6B -8.3B -73.91B -7.76B -7.61B -322B | -18.71B -2.4B -2.28B -2.17B -1.92B -3.44B -207B -3.8B -26.21B -9.62B -85.7B -9B -8.82B -374B |
More financial data
* Estimated data
Employees
20,300
Sector
Pharmaceuticals
Calendar
2025-03-18
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-24 | 4.420 $ | +1.14% | 38,664,950 |
| 25-01-23 | 4.370 $ | -0.23% | 42,935,780 |
| 25-01-22 | 4.380 $ | -1.57% | 38,862,450 |
| 25-01-21 | 4.450 $ | +0.91% | 36,960,410 |
| 25-01-20 | 4.410 $ | +0.23% | 58,172,430 |
Delayed Quote Hong Kong S.E., January 24, 2025 at 03:08 am EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
4.420HKD
Average target price
7.115HKD
Spread / Average Target
+60.97%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1093 Stock